Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Hidetaka Iwamizu"'
Autor:
Toshihiko Wakabayashi, Takenori Kato, Motokazu Ito, Hiroshi Toda, Kazuya Motomura, Hidetaka Iwamizu, Yutaka Kondo, Atsushi Natsume, Masasuke Ohno
Supplementary Data from The Modulation of MicroRNAs by Type I IFN through the Activation of Signal Transducers and Activators of Transcription 3 in Human Glioma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::449284e36d327fd161e57ae7664a8173
https://doi.org/10.1158/1541-7786.22518439
https://doi.org/10.1158/1541-7786.22518439
Autor:
Toshihiko Wakabayashi, Takenori Kato, Motokazu Ito, Hiroshi Toda, Kazuya Motomura, Hidetaka Iwamizu, Yutaka Kondo, Atsushi Natsume, Masasuke Ohno
Type I IFNs are involved in double-stranded RNA responses. Here, we investigated the possibility that IFN-β may induce or downregulate cellular microRNAs (miRNA) in human neoplasms and thereby use the RNA interference system to show antitumor effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4224f95de26e71358235c16cec1c3f47
https://doi.org/10.1158/1541-7786.c.6541912.v1
https://doi.org/10.1158/1541-7786.c.6541912.v1
Autor:
Risa, Araki, Hidetaka, Iwamizu, Tomomi, Kataoka, Yasuo, Kumakura, Masayuki, Miyazaki, Taku, Nagai, Yuichi, Ando, Kiyofumi, Yamada
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 44(2)
Nedaplatin(NDP)is a platinum derivative anticancer drug.An NDP dose of 100mg/m2 every 4 weeks is recommended in non-elderly Japanese patient because a higher dose may lead to myelosuppression, such as thrombocytopenia.In a pharmacokinetic analysis, t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a6dc4257628d9fd32d21696e4bf8e7ac
https://pubmed.ncbi.nlm.nih.gov/28223671
https://pubmed.ncbi.nlm.nih.gov/28223671
Autor:
Hidetaka Iwamizu, Masayuki Miyazaki, Taku Nagai, Akiko Ota, Yasuo Kumakura, Ayaka Itoh, Yuki Kawarada, Risa Araki, Kiyofumi Yamada, Tomomi Kataoka
Publikováno v:
International journal of clinical oncology. 22(3)
Background: Nedaplatin (NDP)-related hypersensitivity reactions (HSRs) trigger adverse clinical events. Prediction and prevention of NDP-HSRs are thus essential to minimize the risk and maximize the benefit of NDP therapy. However, the incidence of N
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ec5933bd0410b00ab22dd2f9284f827
https://pubmed.ncbi.nlm.nih.gov/28124284
https://pubmed.ncbi.nlm.nih.gov/28124284
Autor:
Motokazu Ito, Masasuke Ohno, Ken Ichiro Iwami, Daiki Ito, Kazuya Motomura, Jun Yoshida, Yuki Toi, Kazuhiro Yoshikawa, Atsushi Natsume, Hidetaka Iwamizu, Toshihiko Wakabayashi, Kana Noritake
Publikováno v:
Cancer Science. 101:2518-2524
The isotype of epidermal growth factor receptor variant III (EGFRvIII) is often identified in glioblastomas. Previously, we created a mouse monoclonal antibody, 3C10 (IgG2b), that specifically recognized EGFRvIII, and a recombinant single-chain varia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b84d92e349b26ae7422b0a02ae4e151
https://doi.org/10.1111/j.1349-7006.2010.01734.x
https://doi.org/10.1111/j.1349-7006.2010.01734.x
Autor:
Hiroshi Toda, Motokazu Ito, Yutaka Kondo, Atsushi Natsume, Takenori Kato, Hidetaka Iwamizu, Kazuya Motomura, Masasuke Ohno, Toshihiko Wakabayashi
Publikováno v:
Molecular Cancer Research. 7:2022-2030
Type I IFNs are involved in double-stranded RNA responses. Here, we investigated the possibility that IFN-β may induce or downregulate cellular microRNAs (miRNA) in human neoplasms and thereby use the RNA interference system to show antitumor effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e50b80ca5d4d928647642e91f560583
https://doi.org/10.1158/1541-7786.mcr-09-0319
https://doi.org/10.1158/1541-7786.mcr-09-0319
Autor:
R Watanabe, Krystof S. Bankiewicz, R Hachisu, Hidetaka Iwamizu, Takenori Kato, Hiroshi Toda, Kanako Yuki, Atsushi Natsume, Kazuya Motomura, Toshihiko Wakabayashi, T Sugita
Publikováno v:
Gene therapy. 17(11)
Glioblastoma multiforme (GBM) is one of the most formidable brain tumors with a mean survival period of approximately 12 months. To date, a combination of radiotherapy and chemotherapy with an oral alkylating agent, temozolomide (TMZ), has been used
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fa973ad142186271f6ff225f25d513d
https://pubmed.ncbi.nlm.nih.gov/20520650
https://pubmed.ncbi.nlm.nih.gov/20520650